Description
InformationPQR620 is a novel, selective, orally bioavailable and brain penetrant dualTORC1/2inhibitor. PQR620 has anti-tumor activity across 56 lymphoma models with a median IC50 of 250 nM after 72 h of exposure.TargetsTORC1 (Cell-based assay); TORC2 (Cell-free assay) 250 nM; 250 nMIn vitroPQR620 is a novel brain penetrant dual TORC1/2 inhibitor with anti-tumor activity across 56 lymphoma cell lines with a median IC50 value of 250 nM after 72 h of exposure.In vivoPQR620 has in vivo anti-lymphoma activity and in vivo synergism with the BCL2 inhibitor venetoclax. The combination of PQR620 and venetoclax have stronger in vivo anti-tumor activity than the single agents in a xenograft model of GCB-DLBCL.Cell Research(from reference)Cell lines：56 lymphoma cell lines, ABC-DLBCL cell lines (TMD8, Ri-1), GCB-DLBCL cell lines (OCI-LY-1,SU-DHL-6, DoHH2) Concentrations：2 µM Incubation Time：24 h, 72 h